Search research articles
Contact Us
Filters
Showing results (81-90 of 256) with videos related to
Page
of 26
Sort By:
Plos One
|
August 15, 2019
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, et al.
JAMA Dermatology
|
June 4, 2025
Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis
Zenas Z N Yiu, Catherine H Smith, Philip Laws, et al.
American Journal of Clinical Dermatology
|
February 10, 2024
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
American Journal of Clinical Dermatology
|
January 18, 2024
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
The British Journal of Dermatology
|
January 10, 2025
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
Rheumatology and Therapy
|
August 9, 2024
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Advances in Therapy
|
September 23, 2020
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
Linda Stein Gold, Javier Alonso-Llamazares, Jean-Philippe Lacour, et al.
The British Journal of Dermatology
|
June 10, 2024
Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
David Rutkowski, Rachel Scholey, John Davies, et al.
Rheumatology and Therapy
|
March 15, 2024
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Richard B Warren, Iain B McInnes, Peter Nash, et al.
Rheumatology and Therapy
|
March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Page
of 26
Search research articles
Search
Showing results (81-90 of 256) with videos related to
Sort By:
Page
of 26
Plos One
|
August 15, 2019
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, et al.
JAMA Dermatology
|
June 4, 2025
Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis
Zenas Z N Yiu, Catherine H Smith, Philip Laws, et al.
American Journal of Clinical Dermatology
|
February 10, 2024
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
American Journal of Clinical Dermatology
|
January 18, 2024
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
The British Journal of Dermatology
|
January 10, 2025
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
Rheumatology and Therapy
|
August 9, 2024
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Advances in Therapy
|
September 23, 2020
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
Linda Stein Gold, Javier Alonso-Llamazares, Jean-Philippe Lacour, et al.
The British Journal of Dermatology
|
June 10, 2024
Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
David Rutkowski, Rachel Scholey, John Davies, et al.
Rheumatology and Therapy
|
March 15, 2024
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Richard B Warren, Iain B McInnes, Peter Nash, et al.
Rheumatology and Therapy
|
March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Page
of 26